Jump to content

Helping Canada


KatieB

Recommended Posts

The Canadian Cancer Survivor Network (CCSN), along with several other patient groups, have created a document for a submission to the pan Canadian Oncology Drug Review (pCODR). The submission is for a targeted therapy for cancers that are TRK Gene Fusion Positive and this includes several cancers including: thyroid, sarcoma, colorectal, lung and several paediatric cancers. TRK gene fusion positive cancers, simply put, is rare in common cancers but common in rare cancers. The CCSN is requesting input from patients or their caregivers on their perspective on this new targeted therapy, latrotectinib, that was recently approved by the FDA. Your input will help patients in Canada! Please participate in this 5-minute survey.

Larotrectinib survey for TRK Gene Fusion-positive cancers:  https://www.surveymonkey.com/r/ZNHFWKF

  

Link to comment
Share on other sites

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.

Guest
Reply to this topic...

×   Pasted as rich text.   Restore formatting

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

×
×
  • Create New...

Important Information

By using this site, you agree to our Terms of Use.